InvestSMART

Neurizon Therapeutics Limited (ASX: NUZ) - Announcements

- Current share price for NUZ : $0.079

ASX company news and announcements for Neurizon Therapeutics Limited (NUZ) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neurizon Therapeutics Limited (NUZ) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neurizon Therapeutics Limited (NUZ), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neurizon Therapeutics Limited (NUZ)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$63 Notification of cessation of securities - NUZ 15 Sep 2026 6:17PM $0.075 $0.079 risen by 5.33%
$63 Neurizon Announces Partial Redemption of Convertible Notes 10 Sep 2026 9:53AM $0.085 $0.079 fallen by 7.06%
$63 Application for quotation of securities - NUZ 10 Sep 2026 9:18AM $0.085 $0.079 fallen by 7.06%
$63 NIH funds Expanded Access Program for NUZ-001 in ALS 9 Sep 2026 9:55AM $0.062 $0.079 risen by 27.42%
$63 Neurizon Appoints Chief Executive Officer 7 Sep 2026 9:02AM $0.056 $0.079 risen by 41.07%
$63 Application for quotation of securities - NUZ 26 Aug 2026 11:49AM $0.058 $0.079 risen by 36.21%
$63 Appendix 4G and Corporate Governance Statement 25 Aug 2026 3:03PM $0.057 $0.079 risen by 38.60%
$63 Appendix 4E and 2026 Annual Report 25 Aug 2026 2:58PM $0.057 $0.079 risen by 38.60%
$63 Notification regarding unquoted securities - NUZ 24 Aug 2026 5:06PM $0.059 $0.079 risen by 33.90%
$63 Elanco representative appointed as Neurizon Board Observer 13 Aug 2026 9:46AM $0.067 $0.079 risen by 17.91%
$63 Neurizon Completes Initial Drawdown under R&D Facility 11 Aug 2026 9:47AM $0.068 $0.079 risen by 16.18%
$63 Appendix 4C & Quarterly Update 31 Jul 2026 3:32PM $0.057 $0.079 risen by 38.60%
$63 Neurizon Enters Strategic R&D Financing Facility 31 Jul 2026 3:21PM $0.057 $0.079 risen by 38.60%
$63 Melbourne investor briefing presentation 29 Jul 2026 1:56PM $0.060 $0.079 risen by 31.67%
$63 HEALEY Enrolment Complete - Topline Accelerated to Q2 CY27 17 Jul 2026 9:25AM $0.063 $0.079 risen by 25.40%
$63 Application for quotation of securities - NUZ 16 Jul 2026 11:39AM $0.066 $0.079 risen by 19.70%
$63 Notification of cessation of securities - NUZ 14 Jul 2026 4:36PM $0.064 $0.079 risen by 23.44%
$63 Neurizon Invites Investors to Melbourne Briefing 2 Jul 2026 9:20AM $0.060 $0.079 risen by 31.67%
$63 Change of Director's Interest Notice 1 Jul 2026 9:48AM $0.060 $0.079 risen by 31.67%
$63 Proposed issue of securities - NUZ 30 Jun 2026 9:13AM $0.059 $0.079 risen by 33.90%
$63 Notification of cessation of securities - NUZ 29 Jun 2026 4:31PM $0.059 $0.079 risen by 33.90%
$63 New NUZ-001 Mechanistic Data Presented at BIO 2026 23 Jun 2026 11:25AM $0.061 $0.079 risen by 29.51%
$63 Application for quotation of securities - NUZ 19 Jun 2026 11:15AM $0.066 $0.079 risen by 19.70%
$63 Neurizon executes long-term supply agreement with Elanco 17 Jun 2026 9:07AM $0.063 $0.079 risen by 25.40%
$63 HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule 12 Jun 2026 9:07AM $0.060 $0.079 risen by 31.67%

1 - 25 of 183 results

Page 1 of 8

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.